With this launch, Lupin's FY26 revenue opportunity is estimated at $150–200 million. gTolvaptan could contribute over 25% to ...

The drug, a copy of Jynarque, could add up to $200 million in annual revenue by FY26, strengthening Lupin’s foothold in ...

Lupin gains US FDA approval for Tolvaptan tablets in various dosages, marking a significant entry into the nephrology market.

Australian regenerative food and agriculture company Wide Open Agriculture (WOA) has signed an offtake and distribution ...

Nomura recommends Buy for Dr. Reddy’s, Cipla, Lupin, Zydus amid pharma stock pressure. Check latest market trends!

Pharma major Lupin Ltd on Thursday said it has received approval from the US health regulator for its generic version of ...

In a groundbreaking achievement, Lupin Limited has set a new benchmark in Real-World Evidence (RWE) research by successfully ...

Lupin receives USFDA approval for its generic version of Tolvaptan tablets, indicated for autosomal dominant polycystic ...

Lupin, operating in the Pharmaceuticals sector and classified as a Largecap on the BSE, currently has its share price at ₹2101.75. The stock has experienced fluctuations today, with a low of ...

The approval includes multiple strengths: 15mg, 30mg, 45mg, 60mg, and 90mg, allowing for flexible dosing options.

Lupin Diagnostics achieves NABL certification for all greenfield labs: Our Bureau, Bengaluru Wednesday, April 23, 2025, 12:40 Hrs [IST] Lupin Diagnostics, a wholly owned subsidiar ...

Mumbai: Indian generics drug maker, Lupin wholly owned diagnostic arm Lupin Diagnostics Limited (LDL) has obtained NABL (National Accreditation Board for Testing and Calibration Laboratories ...